



HR0723

LRB104 21017 LAW 34920 r

1

HOUSE RESOLUTION

2           WHEREAS, Serious mental illnesses like bipolar disorder,  
3 major depressive disorder, and schizophrenia often require  
4 treatment with antipsychotic medications for effective  
5 management, and antipsychotic prescribing rates continue to  
6 rise; and

7           WHEREAS, While prolonged antipsychotic use may be  
8 essential for the treatment of certain conditions, it is  
9 associated with tardive dyskinesia (TD), a condition marked by  
10 uncontrollable, abnormal, and repetitive movements of the  
11 face, torso, limbs, or extremities; and

12           WHEREAS, People at higher risk of TD include those older  
13 than 55 years, people who are Black, women, individuals with  
14 mood or substance use disorders, intellectual disabilities, or  
15 central nervous system injuries, and those with high  
16 cumulative antipsychotic exposure; and

17           WHEREAS, Approximately 60% of the estimated 800,000 U.S.  
18 adults living with TD remain undiagnosed, and even mild TD  
19 symptoms can be stigmatizing and impair physical, social, and  
20 emotional well-being, underscoring the urgency of early  
21 screening, detection, and intervention; and

1           WHEREAS, The American Psychiatric Association recommends  
2 routine TD screening in their clinical guidelines for  
3 antipsychotic treatment, and individuals treated with  
4 antipsychotics or experiencing abnormal movements should  
5 consult their health care providers to assess TD risk, receive  
6 TD screenings, and determine appropriate treatment together;  
7 and

8           WHEREAS, FDA-approved treatments for TD can provide  
9 options for symptom management and improved quality of life  
10 for many individuals living with TD; and

11           WHEREAS, The General Assembly can encourage TD screening  
12 education and awareness for health care providers, patients,  
13 and care partners to help ensure patients prescribed  
14 antipsychotics receive care and support that aligns with  
15 clinical best practices, including regular TD screenings;  
16 therefore, be it

17           RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE  
18 HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that  
19 we declare May 3 through May 9, 2026 as Tardive Dyskinesia  
20 Awareness Week (TDAW) in the State of Illinois; and be it  
21 further

22           RESOLVED, That we support TDAW in recognition of the

1 importance of early detection and intervention to improve  
2 outcomes for people living with mental health conditions and  
3 prescribed antipsychotics, and we support efforts to raise  
4 awareness about the causes and symptoms of tardive dyskinesia  
5 (TD) and the importance of routine TD screening.